Please use this identifier to cite or link to this item:
https://hdl.handle.net/2440/54120
Citations | ||
Scopus | Web of Science® | Altmetric |
---|---|---|
?
|
?
|
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Ahern, M. | - |
dc.contributor.author | Campbell, D. | - |
dc.contributor.author | Weedon, H. | - |
dc.contributor.author | Papangelis, V. | - |
dc.contributor.author | Smith, M. | - |
dc.date.issued | 2008 | - |
dc.identifier.citation | Annals of the Rheumatic Diseases, 2008; 67(9):1339-1342 | - |
dc.identifier.issn | 0003-4967 | - |
dc.identifier.issn | 1468-2060 | - |
dc.identifier.uri | http://hdl.handle.net/2440/54120 | - |
dc.description.abstract | Objective: To demonstrate the efficacy of intra-articular infliximab in a patient with a persistent monarthritis who had previously had two arthroscopic synovectomies with limited success, and to determine the effect of intra-articular infliximab on synovial membrane pathology Method: Arthroscopic synovial biopsy specimens were collected before and after treatment with intra-articular infliximab. The synovial tissue was stained for a range of inflammatory cell subsets, cell adhesion molecules and cytokines using immunohistochemical techniques and quantified using digital image analysis and a semiquantitative scoring method. Results: Clinical improvement in the knee synovitis was seen after the first two intra-articular infliximab treatments, with a sustained clinical remission lasting for more than 12 months after the third treatment. Significant changes in cellular infiltration and expression of cytokines and cell adhesion molecules occurred as a result of treatment with intra-articular infliximab, with a reduction in some but not all cells in the inflammatory infiltrate, as well as a reduction in the expression of cell adhesion molecules (intercellular adhesion molecule-1 and vascular adhesion molecule-1) and production of cytokines (interleukin 1β and tumour necrosis factor α). Conclusion: Intra-articular infliximab administration is a viable treatment for a persistent monarthritis resistant to other treatment options and can successfully modulate the inflammatory milieu within the synovial membrane. | - |
dc.description.statementofresponsibility | M J Ahern, D G Campbell, H Weedon, V Papangelis, M D Smith | - |
dc.language.iso | en | - |
dc.publisher | British Med Journal Publ Group | - |
dc.source.uri | http://dx.doi.org/10.1136/ard.2008.090910 | - |
dc.subject | Synovial Membrane | - |
dc.subject | Humans | - |
dc.subject | Spondylarthropathies | - |
dc.subject | Synovitis | - |
dc.subject | Antirheumatic Agents | - |
dc.subject | Antibodies, Monoclonal | - |
dc.subject | Biopsy | - |
dc.subject | Injections, Intra-Articular | - |
dc.subject | Adult | - |
dc.subject | Female | - |
dc.subject | Infliximab | - |
dc.title | Effect of intra-articular infliximab on synovial membrane pathology in a patient with a seronegative spondyloarthropathy | - |
dc.type | Journal article | - |
dc.identifier.doi | 10.1136/ard.2008.090910 | - |
pubs.publication-status | Published | - |
dc.identifier.orcid | Campbell, D. [0000-0002-1572-9529] | - |
Appears in Collections: | Aurora harvest Orthopaedics and Trauma publications |
Files in This Item:
There are no files associated with this item.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.